Skip to main content


Kidney Cancer

Featured

News
Pembrolizumab plus axitinib is associated with greater QALYs compared with nivolumab plus ipilimumab for patients with advanced RCC, but may not be cost-effective.
Conference Coverage
Nivolumab in combination with ipilimumab is a potential cost-effective treatment option for patients with intermediate…
News
Percutaneous cryoablation may be as effective as surgery for treating stage I renal cell carcinoma, according to the…
News
The risk of recurrence in surgically treated renal-cell carcinoma persists beyond 5 years after surgery, suggesting the…
Podcast
Toni Choueiri, MD, discusses surgical considerations and multidisciplinary care for localized kidney cancer, adjuvant…
Back to Top